A Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose-Escalation Study to Access the Safety, Pharmacokinetics, and Pharmacodynamics of ICA-17043 in Patients with Sickle Cell Disease who are in the Steady, Non-Crisis State